Early detection of the human papillomavirus (HPV) is one of the key tools in preventing cervical cancer. The HPV test, an advanced molecular test, replaced the Pap (PAP) test in 2021, which had been in use until then, and today constitutes a significant milestone in the early detection of the virus and of strains associated with a high risk of disease development.
LEM Laboratory of the Mor Institute Group and Clalit Health Services recently announced the completion of its one-millionth HPV test. The laboratory is the largest in Israel in the field of pathological testing, performing approximately 500,000 biopsies of various types each year.
The laboratory prepared in advance for the introduction of HPV testing and acquired a unique device - the only one of its kind in the country - capable of identifying 14 strains of the human papillomavirus that are considered high risk for the development of cervical cancer. The device provides an accurate result, enabling tailored follow-up and treatment according to the detected strain and its risk level.
In cases where the test result is negative and no HPV is detected, the woman receives a response within about a week, can continue her routine life, and is advised to be tested again once every five years. In the case of a positive result, the woman undergoes additional diagnostic stages, including a Pap smear test, for precise identification of the virus and continuation of treatment or follow-up.
According to Ruth Baruch, CEO of L.E.M., about a year ago the laboratory also began performing self-tests for the detection of HPV. The test is conducted in cooperation with Clalit Health Services’ Southern District and is based on samples collected independently by women themselves. The self-test is intended primarily for women who do not visit a gynecologist and are not routinely tested, with the goal of enabling them to participate in this important screening program.
To date, approximately 430 self-tests have been performed, of which around 20 women received a positive result. These women were referred to a gynecologist for further testing and additional medical evaluation. In light of the success of the process, Baruch notes that an expansion of the self-testing program to additional locations across the country is currently being planned.
The HPV test is provided free of charge once every five years for women aged 25 and older. In cases where one of the virus strains is detected, treatment is carried out by a gynecologist and includes close monitoring or tailored medical treatment, depending on the clinical condition. As part of the effort to eradicate cervical cancer in Israel, routine vaccination against the human papillomavirus is administered in schools, for both girls and boys. The laboratory recommends that parents vaccinate their children as part of long-term disease prevention.